Costs and Effects of Various Analgesic Treatments for Patients with Rheumatoid Arthritis and Osteoarthritis in The Netherlands  by Al, Maiwenn J. et al.
Costs and Effects of Various Analgesic Treatments for
Patients with Rheumatoid Arthritis and Osteoarthritis in
The Netherlands
Maiwenn J. Al, PhD,1 Nikos Maniadakis, PhD,2 Els W. M. Grijseels, PhD, MD,3 Matthijs Janssen, PhD, MD4
1Institute for Medical Technology Assessment, Erasmus MC, Rotterdam,The Netherlands; 2Patras University General Hospital, Patras, Greece;
3Department of Gynecology and Obstetrics, Erasmus MC, Rotterdam,The Netherlands; 4Department of Rheumatology, Rijnstate Hospital,
Arnhem,The Netherlands
ABSTRACT
Objective: To assess the balance between costs and upper
gastrointestinal (GI) side effects of treatment with celecoxib,
nonsteroidal antiinﬂammatory drugs (NSAIDs) alone,
NSAID plus misoprostol, NSAID plus histamine-2 receptor
antagonist (H2RA), NSAID plus proton pump inhibitor (PPI),
and Arthrotec in The Netherlands.
Methods: A model was used to convene data from various
sources on the probability of GI side effects and resource use.
The probabilities of GI side effects for celecoxib and NSAIDs
alone were derived from trial data. Calculations were based
on 6 months of treatment, and were from a societal perspec-
tive. Distinction was made between low-, medium-, and high-
risk patients. An extensive probabilistic sensitivity analysis
was performed to address uncertainty.
Results: Assuming an average patient, the total costs per
6 months of therapy were: celecoxib €255, NSAIDs alone
€166, NSAID plus misoprostol €285, NSAID plus H2RA
€284, NSAID plus PPI €243, and Arthrotec €187. Treatment
with celecoxib was associated with the lowest number of GI
side effects and related deaths. Incremental costs per life-year
saved for Arthrotec compared to NSAIDs alone were €5676
for all patients and €526 for medium-to-high-risk patients,
whereas for high-risk patients, Arthrotec dominated NSAID
alone. For celecoxib compared to Arthrotec, the incremental
cost-effectiveness ratios (ICERs) were €56,667, €33,684, and
€15,429, respectively.
Conclusion: Assuming a limit of €20,000 per life-year
gained, from an economic point of view, Arthrotec is the
preferred treatment when all patients or medium-to-high-risk
patients are considered. In high-risk patients, celecoxib is the
preferred treatment strategy.
Keywords: arthritis, celecoxib, cost-effectiveness, NSAIDs,
selective COX-2 inhibitors.
Introduction
Rheumatoid arthritis (RA) is a chronic disease, which
features persistent synovitis, especially in the smaller
joints. Osteoarthritis (OA) is a degenerative joint
disease characterized by pain and stiffness. The preva-
lence of both diseases is high: in the Dutch adult popu-
lation, the prevalence of RA is estimated at 1.2%,
which amounts to 150,000 patients; the prevalence of
OA increases with age and has been estimated at 5%,
equivalent to 600,000 patients (based on patients with
complaints visiting their general practitioner [GP]) [1].
Nevertheless, not all OA patients require medical
attention. A previous study in The Netherlands has
shown that GPs deem further treatment necessary in
only one-third of OA patients (i.e., 200,000 patients)
[1]. Another study showed that of OA patients aged
50 years or older, 350,000 had pain [2].
Medical therapy for both OA and RA is aimed at
relieving pain, maintaining mobility, and/or reducing
inﬂammation. According to Dutch GP guidelines, the
therapy of ﬁrst choice for RA patients involves a non-
steroidal antiinﬂammatory drug (NSAID), whereas for
OA patients ﬁrst-line therapy is paracetamol. Never-
theless, if the analgesic effect is insufﬁcient or if inﬂam-
mation occurs, OA patients should be switched to an
NSAID.
A major disadvantage of chronic NSAID use is the
gastrointestinal (GI) side effects, ranging from abdomi-
nal pain, nausea, and dyspepsia to more serious events
such as gastric or duodenal ulcers, anemia and bleed-
ing, or perforated ulcer (possibly leading to death).
These side effects are due to the simultaneous inhibi-
tion of cyclooxygenase (COX)-1 and COX-2. In
2000, 2823 hospital admissions in The Netherlands
were NSAID-related and 165 patients died as a conse-
quence [3]. A Dutch observational study estimated
that for each €1.00 spent on NSAID therapy, an addi-
tional €0.68 is spent on gastroprotective agents
(GPAs)—including proton pump inhibitors (PPIs),
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histamine-2 receptor antagonists (H2RAs), or
misoprostol—and hospitalization for GI adverse
events [4]. In the past few years, physicians have
increasingly prescribed GPAs with NSAIDs as prophy-
lactic treatment in an effort to reduce GI risks [5].
Celecoxib is a COX-2-speciﬁc inhibitor and, com-
pared to nonspeciﬁc NSAIDs which inhibit both
COX-1 and COX-2, it is associated with signiﬁcantly
fewer GI side effects [6,7]. We studied the balance
between the costs and effects for six different treatment
strategies in The Netherlands. A modeling approach
was used to calculate the costs of drug treatment and
its associated GI side effects.
Methods
Our study encompasses the economic evaluation of six
treatment strategies for pain management in RA and
OA patients, which involves the use of NSAIDs alone,
NSAID plus PPI, NSAID plus H2RA, NSAID plus
misoprostol, Arthrotec (ﬁxed-dose combination of
NSAID plus misoprostol), and celecoxib. A time
horizon of 6 months was used and the analysis was
performed from a societal perspective.
Outcome Measure
The results of this study are presented in an interme-
diate outcome, i.e., the number of averted GI events
(symptomatic ulcer, anemia, and serious GI events
requiring hospitalization), and a ﬁnal outcome, i.e.,
life-years saved, extrapolated from deaths averted
within the 6-month time frame.
A symptomatic ulcer was deﬁned as an ulcer found
during an endoscopy performed because the patient
reported GI complaints. Anemia (with occult bleeding)
was deﬁned as any suspected GI event diagnosed by
the physician as anemia, plus all study withdrawals
due to anemia or “severe” anemia. Serious GI events
were deﬁned as GI discomfort, anemia, symptomatic
ulcer, bleeding ulcer, perforation, or obstruction,
which required hospitalization. Thus, a patient with
anemia who required admission to the hospital was
not counted as having “anemia” but as having a
“serious GI event.”
Model
A decision analytic model was developed to assess the
costs and effects of the various treatment strategies (see
Fig. 1). The patient has a probability of having no GI
side effects, a certain GI side effect, or death due to a
serious GI event. Patients treated with NSAID plus
misoprostol or Arthrotec also have a small probability
of being therapy-intolerant. In this case, they switch to
NSAID plus PPI. The model and the estimation of its
input variables have been previously described by
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Figure 1 Decision tree for rheumatoid arthritis (RA) and osteoarthritis (OA) patients.GI, gastrointestinal;H2RA,histamine-2 receptor antagonist;NSAID,
nonsteroidal anti-inﬂammatory drug; PPI, proton pump inhibitor.
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Burke et al. [8], and are summarized here. For all
events, probabilities for NSAIDs alone and celecoxib
were derived from the pooled Kaplan–Meier estimates
from eight Phase III studies of at least 12 weeks with
parallel celecoxib and NSAID treatment arms. These
studies included a total of 3216 and 2427 patients in
the celecoxib and NSAID treatment groups, respec-
tively. All these studies were included in the meta-
analysis by Deeks et al. [9]; the main difference
between our estimations and those of Deeks et al. is
that here the Celecoxib Long-Term Arthritis Safety
Study (CLASS) was excluded, because of the much
higher dosage of celecoxib studied. For all other treat-
ment strategies, probabilities were estimated using
relative risks compared to NSAIDs alone, as derived
from the literature. Table 1 gives an overview of
6-month probabilities of GI adverse events and relative
risks (compared to NSAIDs alone) for the various
treatment options [10–26].
From large-scale studies in RA and OA patients
using NSAIDs, it has become clear that there are
several important risk factors associated with the
development of serious GI events [27,28]. The main
risk factors are older age (>65 years), use of corticos-
teroids, history of GI discomfort, and/or symptomatic
or bleeding ulcer. Based on these studies, a score
system for GI risk was developed and applied to the
celecoxib clinical trials previously identiﬁed [8,29]. For
every score, a probability is calculated that a patient
will experience a serious GI event. We categorized this
GI risk score into low, medium, and high. Patients with
a probability lower than 0.5% per year were consid-
ered to be at low risk (categories 1–5), patients with a
probability between 0.5% and 1.5% per year were
considered to be at medium risk (categories 6 and 7),
and patients with a probability greater than 1.5% were
considered to be at high risk (category 8 and higher).
Note that patients classiﬁed as high-risk according to
these cut-off points are also considered to be high-risk
patients in various guidelines [3,30].
In the model, it is assumed that the probability of
having a symptomatic ulcer or anemia increases pro-
portionally with the risk of serious GI events (thus
assuming a similar etiology). In addition, it is assumed
that the probability of having moderate-to-severe GI
discomfort is equal for all patients, because there is
little correlation between damage to the mucosa and
GI symptoms.
In the identiﬁed clinical trials, 0.59% of NSAID
patients had serious GI events, compared to 0.23%
of those receiving celecoxib. On average, patients
included in the studies were in risk category 7, and it
has therefore been assumed that the observed prob-
abilities for serious GI events, symptomatic ulcers, and
anemia in these trials are also for patients in this risk
category. The probabilities of a serious GI event for
patients on NSAIDs alone in other risk categories are
derived by adding or subtracting 0.25% per risk cat-
Table 1 Probability and relative risks of adverse GI events by treatment
Adverse event Treatment Probability RR 95% CI Distribution Sources
GI discomfort NSAIDs alone 0.1454 1.00 — Normal RCT
NSAID plus PPI 0.0931 0.64 0.39–1.06 Lognormal [10–12]
NSAID plus H2RA 0.1032 0.71 0.55–0.92 Lognormal [13–15]
NSAID plus misoprostol 0.1730 1.19 1.06–1.33 Lognormal [12,16–21]
Arthrotec 0.1803 1.24 0.99–1.57 Lognormal [22–26]
Celecoxib 0.0940 0.65 0.54–0.78 Lognormal RCT
Symptomatic ulcers NSAIDs alone 0.0628 1.00 — Normal RCT
NSAID plus PPI 0.0207 0.33 0.24–0.44 Lognormal [7–9]
NSAID plus H2RA 0.0408 0.65 0.44–0.95 Lognormal [13,15]
NSAID plus misoprostol 0.0251 0.40 0.31–0.51 Lognormal [12,16,18,20]
Arthrotec 0.0226 0.36 0.26–0.51 Lognormal [22–26]
Celecoxib 0.0174 0.28 0.17–0.45 Lognormal RCT
Serious GI events NSAIDs alone 0.0059 1.00 — Normal RCT
NSAID plus PPI 0.0029 0.50 N/A Lognormal Assumption*
NSAID plus H2RA 0.0058 0.98 N/A Lognormal Assumption*
NSAID plus misoprostol 0.0036 0.60 0.36–0.98 Lognormal [17]
Arthrotec 0.0032 0.54 N/A Lognormal Assumption*
Celecoxib 0.0023 0.39 0.10–1.56 Lognormal RCT
Anemia NSAIDs alone 0.0109 1.00 — Normal RCT
NSAID plus PPI 0.0036 0.33 N/A Lognormal Assumption†
NSAID plus H2RA 0.0071 0.65 N/A Lognormal Assumption†
NSAID plus misoprostol 0.0044 0.40 N/A Lognormal Assumption†
Arthrotec 0.0039 0.36 N/A Lognormal Assumption†
Celecoxib 0.0030 0.28 0.10–0.94 Lognormal RCT
Misoprostol intolerance NSAID plus misoprostol
and Arthrotec
0.0233‡ 0.0051–0.0414 Normal [16–23,26]
*The ratio of ulcers to serious GI events for misoprostol (7.02:1) was used to estimate these probabilities.
†Same relative risks as for ulcers.
‡Risk difference.
CI, conﬁdence interval; GI, gastrointestinal; H2RA, histamine-2 receptor antagonist; NSAID, nonsteroidal antiinﬂammatory drug; PPI, proton pump inhibitor; RCT, randomized
controlled trial; RR, relative risk.
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egory [29]. The probabilities for other treatment strat-
egies are estimated by using the relative risks presented
in Table 1, with the corresponding 95% conﬁdence
intervals (CIs). Note that we assume that the relative
risk does not change according to risk score.
Based on the celecoxib trial results, it was estimated
that after 6 months 6.28% of NSAID patients would
have a symptomatic ulcer compared to 1.74% of
celecoxib-treated patients. It was assumed that these
probabilities match risk category 7, and the probabili-
ties in other risk categories were estimated using
the observed ratio between symptomatic ulcers
and serious GI events (10.52:1). The probabilities of
anemia were estimated in the same way: the estimated
6-month probability of anemia in the NSAID group
was 1.09% and in the celecoxib group 0.30%. The
probabilities in other risk categories were estimated
using the observed ratio between anemia and serious
GI events (1.83:1).
The probability of death resulting from a serious GI
event was estimated at 12% using the data of Fries
et al. [31]. Based on a study by Al et al., we estimated
that every death due to a serious GI event equals the
loss of 10 life-years (after discounting by 4%) [32].
This estimate was based on RA patients only, and thus
might be conservative, because RA patients already
have a lower life expectancy because of the nature of
their illness [33].
Costs
The present study only considers direct medical costs;
production losses are disregarded because of the rela-
tively advanced age of the RA and OA patients and the
short duration of the GI side effects. All costs presented
are 2004 Euros (€).
For NSAID and celecoxib treatment, we assumed
that all OA and 50% of RA patients use the deﬁned
daily dose (DDD) while 50% of RA patients use twice
the DDD. Additionally, we assumed that all OA and
50% of RA patients use Arthrotec at 50/200 twice
daily, while 50% of RA patients use the 75/200 dosage
twice daily. For the dosage of H2RA and PPI the DDD
was assumed, and ﬁnally, for misoprostol only 400 mg/
day (half the DDD) was assumed, because this is com-
parable to the misoprostol dosage in Arthrotec. Based
on the epidemiological data mentioned in the introduc-
tion, we assumed a ratio of RA to OA of 1:1.
To calculate the cost of NSAID treatment, a
weighted average was calculated for the three most
commonly prescribed NSAIDs (based on IMS Health
data 2004): diclofenac (39%), ibuprofen (23%), and
naproxen (14%). This resulted in a weighted average
of €0.44 per day. For the costs of H2RAs we used an
average of ranitidine (83%) and cimetidine (12%),
leading to costs of €0.68 per day. PPI costs were cal-
culated using a weighted average of omeprazole (53%;
50/50 generic/brand), pantoprazole (28%), rabepra-
zole (5%), and lansoprazole (3%), leading to costs of
€0.83 per day. Finally, the costs of misoprostol and
Arthrotec were €0.53 and €0.72 per day, respectively,
and the cost of celecoxib was €1.19 per day.
Resource use associated with GI side effects was
estimated using a hospital database for the number of
in-hospital days due to serious GI events (http://
www.prismant.nl) and an expert panel for all other
items. This expert panel consisted of two GPs, two
rheumatologists, and two gastroenterologists. Table 2
shows the average resource use per patient and the
costs per unit of resource use. Costs per unit for most
resources were calculated in accordance with the
Dutch manual for costing research [34]. Nevertheless,
for surgery, laboratory tests and abdominal x-ray
tariffs were used, as we anticipated that these costs
would only be a small fraction of the total costs. From
Table 2 Resource use for GI adverse events, average per patient plus costs per unit
Symptomatic ulcer Anemia GI discomfort Serious GI events Costs per unit (€)
Specialist outpatient visit 1.25 1.65 0.55 0.66 64
GP outpatient visit 1.25 1.33 0.6 21
Gastroscopy (diagnostic) 0.75 0.75 0.035 0.59 144
Gastroscopy (therapeutic) 0.54 390
Colonoscopy 0.12 0.11 183
Sigmoidoscopy 0.12 132
Abdominal x-ray 0.15 39
Surgery 0.17 1090
Hospital day normal care 11.5 367
Hospital day intensive care 0.11 1734
Hb level and MCV 2 3 0.25 3 1.5
CBC 3 6
Iron level 3 2
PPI low dose* 0.66 (45 days) 0.5 (45 days) 0.83 (day)
PPI high dose† 0.66 (60 days) 1 (45 days) 1.81 (day)
Losec IV 17 vials 10 (vial)
H2RA (deﬁned daily dose) 0.34 (60 days) 0.34 (45 days) 0.25 (45 days) 0.68 (day)
*Low dose: omeprazole 20 mg, pantoprazole 20 mg, rabeprazole 10 mg, lansoprazole 15 mg.
†High dose: omeprazole 40 mg, pantoprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg.
CBC, complete blood count; GI, gastrointestinal; GP, general practitioner; H2RA, histamine-2 receptor antagonist; Hb, hemoglobin; MCV, mean corpuscular volume; PPI, proton
pump inhibitor.
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this, we estimated the following costs per GI adverse
event: moderate to severe GI discomfort €78; symp-
tomatic ulcer €309; anemia €344, and serious GI
events €5244.
Sensitivity Analysis
Uncertainty about costs, effects, and cost-effectiveness
were assessed using a probabilistic sensitivity analysis
(PSA) and univariate analyses. In the PSA, all param-
eters were varied simultaneously in 5000 simulations
[35]. These simulations were performed using Tree-
AgePro 2005. For every simulation, a value of the
parameter was drawn from its probability distribution.
For the probabilities of events (plus that of “no GI
event”) the multivariate Dirichlet distribution was
assumed. The parameters were derived such that they
corresponded to the probabilities presented in Table 1,
and to the uncertainty observed in the clinical study in
the NSAID and celecoxib group and around the rela-
tive risks presented in Table 1 for the other groups (see
Table 3). For the probability of death after a serious GI
event and the probability of misoprostol intolerance,
normal distributions were assumed. Furthermore, for
costs triangular distributions were assumed, with
limits of 35% for the costs of GI discomfort and
anemia, and of 20% for the costs of symptomatic
ulcers and serious GI events. Different percentages
were used to reﬂect a difference in uncertainty about
the cost estimates—for GI discomfort and anemia,
there is more practice variation in diagnostics and
treatment between physicians.
The results of the PSA are presented using cost-
effectiveness (C/E)-acceptability curves, constructed
for every treatment strategy [36,37]. These curves
show, for every limit society may put on the costs per
life-year gained (willingness-to-pay [WTP]), the prob-
ability that the treatment considered will be the most
favorable.
In the univariate analyses, each parameter was
varied one at a time between the upper and lower
limits of the CIs. For key parameters, the value could
be varied beyond the limits of the CIs, for instance, to
translate values from a study setting to daily clinical
practice.
Results
Risk Distribution
A total of 6779 patients were included in the eight
clinical trials in which celecoxib was compared to an
NSAID and/or placebo. For each of these patients the
risk score was calculated and a category assigned.
When medium risk was deﬁned by risk categories 6
and 7, we found that 36.6% of patients had a low risk,
37.9% a medium risk, and 25.5% a high risk of
serious GI events.
GI Adverse Events
Treatment with NSAID plus PPI will lead to 9.3% of
patients having moderate to severe GI discomfort,
compared to 9.4% with celecoxib, 10.3% with NSAID
plus H2RA, 14.5% with NSAIDs alone, 17.1% with
NSAID plus misoprostol, and 17.8% with Arthrotec®.
Table 4 shows the number of other GI adverse
events (symptomatic ulcer, anemia, and serious GI
events) for the various treatment options. Focusing on
subgroups (i.e., excluding low- or even medium-risk
patients) reveals a sharp increase in the number of
adverse events per 1000 patients treated. Furthermore,
Table 4 shows the number of deaths due to serious GI
adverse events when 1000 patients receive one of the
treatment alternatives. The number of deaths is largest
for treatment with NSAIDs alone or NSAID plus
H2RA, and smallest in patients treated with celecoxib.
Costs
Table 4 presents the total costs per patient (i.e., costs of
initial therapy plus costs of treating GI side effects)
during 6 months for the various treatment strategies.
NSAID alone is the least expensive in all patients
and in medium-to-high-risk patients. For high-risk
patients, Arthrotec is the least expensive. The most
expensive is treatment with NSAID plus PPI or NSAID
plus H2RA.
Cost-Effectiveness
The results in Table 4 show that treatment with
NSAID plus H2RA and NSAID plus misoprostol are
dominated by Arthrotec and treatment with NSAID
plus PPI is dominated by celecoxib. Following the deci-
Table 3 Parameters of Dirichlet distribution used in the probabilistic sensitivity analysis for patients with risk score 7
Celecoxib
NSAID
alone
NSAID
plus PPI
NSAID
plus H2RA
NSAID plus
misoprostol Arthrotec
No GI event 618 1163 440 624 635 395
GI discomfort 66 218 47 77 138 90
Anemia 2 16 2 5 4 2
Symptomatic ulcer 12 94 10 30 20 11
Serious GI event 2 9 1 4 3 2
GI, gastrointestinal; H2RA, histamine-2 receptor antagonist; NSAID, nonsteroidal antiinﬂammatory drug; PPI, proton pump inhibitor.
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sion rules of Karlsson and Johannesson, ICERs can
be calculated for Arthrotec compared to NSAID alone,
and for celecoxib compared to Arthrotec (see Table 5)
[38]. For high-risk patients, NSAID alone is also
dominated by Arthrotec, so for that subgroup only
the comparison between Arthrotec and celecoxib is
relevant.
Sensitivity Analysis
Figure 2 shows the family of C/E-acceptability curves
that result from the PSA. When all patients are con-
sidered, while assuming a WTP of €20,000 per life-
year saved as acceptable [39,40], NSAID alone has a
44% probability of being the most cost-effective given
all uncertainty about the model input, while this prob-
ability is 38% for Arthrotec and 15% for celecoxib.
For the other treatments the probability of being the
most favorable is negligible. Conversely, for medium-
to-high-risk patients, Arthrotec has a 59% probability
of being most cost-effective, while this probability is
26% for celecoxib and 10% for NSAID alone. When
only the high-risk patients are considered, celecoxib
has the highest probability of being the most favorable
treatment at 48% versus 41% for Arthrotec.
The univariate sensitivity analysis showed that most
of the uncertainty around the ICER results from uncer-
tainty associated with the probability of a serious GI
event when taking NSAIDs alone and uncertainty
around the relative risk of a serious GI event for
Arthrotec and celecoxib. It is not surprising that these
parameters are the most uncertain, as serious GI events
are relatively rare. We also changed two parameters
beyond the limits of the CI: the probability of GI
discomfort was decreased by 50% (to 7.5%) and the
probability of a symptomatic ulcer was decreased by
85% (thus setting the ratio of symptomatic ulcer vs.
serious GI event to 1:1 instead of 10.5:1). These
changes altered the ICERs to some extent, but not to
the extent that the conclusions regarding the accept-
ability of the outcome changed.
Discussion
We studied the balance between costs and effects of six
treatment strategies for pain management used in stan-
dard practice in The Netherlands, using a modeling
approach. We distinguished three risk groups and
showed that judgment regarding the balance between
costs and effects differs depending on which subset of
RA/OA patients is treated.
The ﬁrst important observation from our results is
that NSAID plus PPI, NSAID plus H2RA, and NSAID
plus misoprostol are all dominated treatments, regard-
less of subgroup considered. If we consider all patients
or the group of medium- and high-risk patients, treat-
ment with Arthrotec may be considered cost-effective
compared to NSAIDs alone (when assuming a WTP of
€20,000), but compared to Arthrotec, celecoxib is not
Table 4 Number of GI side effects (symptomatic ulcer, anemia, serious GI event), deaths due to GI side effects, and total costs (2004
€) per 1000 patients treated, for each treatment alternative with a follow-up of 6 months; treatment strategies are sorted according to
their effects
All patients
Medium- and high-risk
patients High-risk patients
GI side
effects Deaths
Costs
(¥1000)
GI side
effects Deaths
Costs
(¥1000)
GI side
effects Deaths
Costs
(¥1000)
NSAID alone 87.9 0.80 166 135.2 1.23 198 248.1 2.25 271
NSAID plus H2RA 59.1 0.78 284 90.8 1.20 309 166.7 2.21 367
NSAID plus misoprostol 36.2 0.48 243 55.7 0.73 259 102.1 1.34 294
Arthrotec 32.6 0.43 187 50.2 0.66 201 92.1 1.21 234
NSAID plus PPI 30.0 0.40 285 46.2 0.61 298 84.7 1.13 327
Celecoxib 25.0 0.31 255 38.5 0.47 265 70.7 0.86 288
GI, gastrointestinal; H2RA, histamine-2 receptor antagonist; NSAID, nonsteroidal antiinﬂammatory drug; PPI, proton pump inhibitor.
Table 5 Incremental costs (per 1000 patients), incremental effects (per 1000 patients), and incremental costs per life-year gained
(ICER), treatment strategies are sorted according to their effects, dominated treatments have been excluded (2004 €)
All patients Medium- and high-risk patients High-risk patients
DSurvivors
DCosts
(¥1000)
ICER†
(€/LYG) DSurvivors
DCosts
(¥1000)
ICER†
(€/LYG) DSurvivors
DCosts
(¥1000)
ICER†
(€/LYG)
NSAID alone 999.2 166 17 998.8 198 20 Dominated‡
Arthrotec 0.4 21 5,676 0.6 3 526 998.8 234 23
Celecoxib 0.12 68 56,667 0.19 64 33,684 0.35 54 15,429
†The ICER was calculated as DCosts/(10 ¥ DSurvivors), to reﬂect that each death due to serious GI events means the lose of 10 life-years.
‡Treatment is dominated because another treatment with more effects costs less.
LYG, life-year gained; NSAID, nonsteroidal anti-inﬂammatory drug.
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cost-effective for these patient groups. For high-risk
patients, Arthrotec dominates NSAID alone, and cele-
coxib is now cost-effective compared to Arthrotec.
In formulating the conclusions regarding cost-
effectiveness, we have assumed a limit on the ICER of
€20,000 per life-year saved. This explicit value has
been used in The Netherlands for guideline develop-
ment in several therapeutic areas [39,40] and it might
be assumed that this limit is also acceptable for the
prevention of GI adverse events in NSAID treatment.
Alternatively, the acceptability curves presented in
Figure 2 allow decision-makers to choose their own
limit and conclude for themselves which treatment
should be deemed acceptable.
Several other economic evaluations of celecoxib
versus NSAID or NSAID plus GPA have been pub-
lished, all with very different results [41–46]. These
differing results are partly explained by the differences
in the costs. These cost estimates vary by country and
by perspective used. But there are also methodological
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differences, such as the comparator used: many studies
only compare celecoxib to NSAIDs alone [44,45],
whereas Spiegel et al. compared pooled results from
celecoxib and rofecoxib to NSAID alone [43]. Some
studies have used the CLASS as an import source
of data, while we have excluded this study based on
the dosing used [43,44]. Furthermore, most studies
address the uncertainty around the ICER only through
univariate sensitivity analysis, which gives an incom-
plete idea of overall uncertainty [41,45,46]. The only
study in which a PSA was done on all input param-
eters, much like in this article, limited their report to
the ICER of celecoxib versus NSAID alone, while the
baseline estimates showed that Arthrotec was the best
alternative [42].
In this study, “GI events averted” and “life-years
saved” have been used as the effectiveness outcomes.
Neither of these measures perfectly capture the adverse
events associated with NSAID use. Usually, health
economists prefer cost-utility analysis, because the
utility measures the impact of an intervention on both
length of life and quality of life. In this study, however,
the GI adverse events are relatively easy to treat and
their impact on quality of life may be expected to be of
limited duration. Furthermore, no difference in effec-
tiveness in terms of pain relief has been shown between
NSAIDs and celecoxib [9]. Thus, adjusting the life-
years gained for quality of life will have little impact on
the ICER.
An important choice in any cost-effectiveness analy-
sis is the time horizon, 6 months in this study. The time
horizon of a study should, in general, be long enough
to capture all relevant outcomes. It may be argued that
many RA patients use their NSAID continuously, and
that thus the time horizon should be longer. Neverthe-
less, the risk of GI adverse events has been shown to be
time-independent [47]. Thus, the only time-dependent
variable in our model is the probability of misoprostol
intolerance, which is quite low. Furthermore, the costs
in this study occur at the same time as the effects, and
there are no one-time costs at the start of the model.
This means that the inﬂuence of the time horizon of the
model is negligible: the ICER will be (approximately)
the same no matter we use a horizon of 3 months or
3 years (e.g., in a Markov model).
In the current study, we have not included possible
cardiovascular (CV) adverse events related to NSAID
use. There is much debate about whether coxibs as a
class have an increased risk of CV adverse events com-
pared to placebo, and as a result, it is currently recom-
mended not to treat patients with increased risk of CV
events with celecoxib [48], and in general to treat with
celecoxib at the lowest possible dose for the shortest
possible time. Nevertheless, a meta-analysis of obser-
vational studies of NSAIDs and coxibs and their risk of
acute myocardial infarction showed no increased risk
for celecoxib compared to no NSAID (relative risk
0.97, 95% CI 0.86–1.08). Likewise, for NSAIDs the
relative risk was 1.08 (95% CI 0.95–1.22) [49]. Thus,
there is currently no reason to suppose that there is a
difference between NSAID alone and celecoxib regard-
ing CV adverse events. Should at some point become
clear that one of these treatments has an increased risk,
then the CV events should be included in a cost-
effectiveness analysis of celecoxib versus NSAID.
We extensively studied the uncertainty surrounding
the outcomes of the analysis. Much of this uncertainty
is a result of the rather wide CI around the relative risk
of serious GI events for celecoxib. Because the inci-
dence of these events is very small, even the pooled
trial data lack power to ﬁnd a signiﬁcant difference.
Nevertheless, our point estimate is validated by the
CLASS, comparing the upper GI safety of celecoxib at
high dosage (800 mg/day) to that of NSAIDs used at
common dosages (i.e., ibuprofen at 2400 mg/day and
diclofenac at 150 mg/day), in approximately 4000
patients per group [50]. The estimated relative risk for
serious GI events (bleeding, perforation, and obstruc-
tion) was 0.53 (95% CI 0.26–1.11). This relative risk
is slightly higher than the one reported in Table 1, but
well within the 95% CI given in Table 1. In a meta-
analysis by Deeks et al., the eight clinical studies used
in the current analysis were combined with the CLASS
data to estimate overall efﬁcacy and safety of celecoxib
[9]. Nevertheless, we decided against pooling the
CLASS data with the results presented in Table 1 as the
dosage of celecoxib in the CLASS is much higher than
in the previous studies and is higher than the recom-
mended daily dose for The Netherlands. Furthermore,
there have been difﬁculties with the interpretation of
the CLASS because of the potential biases of informa-
tive censoring observed in the trial (preferential with-
drawal of patients with GI risk factors from the
NSAID treatment arm) [51–53].
In addition to the statistical uncertainty resulting
from studying a sample of patients instead of the
whole population, uncertainty also arises when
results of efﬁcacy trials are translated to estimates of
effectiveness in daily practice. Based on the present
study, one might argue that during the clinical trials
both physicians and patients were more alert to
symptoms of GI discomfort and ulcers than in daily
practice. Consequently, the probability of GI discom-
fort and symptomatic ulcers might be an overestima-
tion. We addressed this problem in a separate
univariate sensitivity analysis, which was determined
to have little effect on the conclusions regarding cost-
effectiveness.
A remark should be made with respect to patient
compliance. In the present study, we have assumed
this to be an unrealistic 100%. A Dutch retrospective
observational cohort study showed that the percent-
age of nonadherence to PPI or H2RA during use of
NSAIDs was 37% [54]. Nonadherence was deﬁned as
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PPI or H2RA coverage of less than 75% of NSAID
treatment days. It is not clear how this would affect
the results of the current study, though it might be
expected that the number of GI events would increase
when adherence decreases. Separate, naturalistic
studies comparing combination and single formula-
tion strategies will be necessary to describe effective-
ness in daily practice.
Recently, Dutch guidelines for NSAID use were
published. These recommend that all patients with
increased risk of GI events should receive some form of
prophylaxis, either by addition of a PPI or misoprostol
to an NSAID, or by prescription of a COX-2-speciﬁc
inhibitor [3]. In these guidelines, it is left to the physi-
cian and patient to select the preventive strategy most
suitable for the individual situation, as it is assumed
that the risk reductions of these three treatments are
about the same. A Dutch study analyzing the appro-
priate utilization of preventive strategies in patients
receiving NSAIDs showed that more than 80% of new
NSAID users with one or more risk factors for GI side
effects do not receive any GPA [55]. Clearly, most new
NSAID users are not yet treated according to the
guidelines and it is to be expected that, in the coming
years, more and more patients will receive some form
of protective agent with their NSAID. When there are
no compelling medical reasons to give a patient an
NSAID with a separate GPA, then from an economic
perspective, depending on the risk of the individual
patient, either Arthrotec or celecoxib is the preferred
treatment.
Source of ﬁnancial support: This study was supported by a
grant from Pﬁzer BV, The Netherlands.
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